IP Library Granted Patent US 9,012,468
Granted Patent B2
US 9,012,468 · App. 13/762,431 · Granted Apr 21, 2015

One pot process for producing 6-hydroxyl nal-opiate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,468
App. No.
13/762,431
Granted
Apr 21, 2015
Kind
B2
Abstract

The present invention provides processes for preparing nal-opiates without the isolation of intermediates. In general, the process provides for alkylation and reduction in the same pot to give the nal-opiate.

Claims (37)

1. A one pot process for preparing a 6-hydroxyl nal-opiate from a 6-keto nor-opiate, the process comprising:

(a) contacting the 6-keto nor-opiate with an alkylating reagent to form a 6-keto nal-opiate, wherein the 6-keto nal-opiate is not isolated; and

(b) contacting the 6-keto nal-opiate with a reducing agent and a proton acceptor to form the 6-hydroxyl nal-opiate;

wherein the reducing agent is selected from the group consisting of a sulfinic acid reducing agent, a hydrosulphite, a borohydride reagent, an aluminum hydride reagent, and a catalytic hydrogen transfer reduction reagent;

wherein the catalytic hydrogen transfer reduction reagent comprises a transition metal and a hydrogen donor, the transition metal being selected from the group consisting of palladium and platinum; and

wherein the process further comprises addition of a protic solvent after step (a).

2. The process of claim 1 , wherein the alkylating reagent comprises an alkyl halide and the reducing agent is chosen from a hydrosulphite, a sulfinic acid reducing agent, a borohydride reagent, and a catalytic hydrogen transfer reduction regent.

3. The process of claim 1 , wherein a 6-β-epimer of 6-hydroxyl nal-opiate is produced in a ratio of greater than 75:25 to a 6-α-epimer.

4. The process of claim 1 , wherein a 6-α-epimer of 6-hydroxyl nal-opiate is produced in a ratio of greater than 75:25 to a 6-β-epimer.

5. A one pot process for producing a compound comprising Formula (I) from a compound comprising Formula (II), the process comprising:

(a) contacting the compound comprising Formula (II) with an alkylating reagent comprising R 17 to form an intermediate comprising Formula (III), wherein the intermediate comprising Formula Op is not isolated; and

(b) contacting the intermediate comprising Formula (III) with a reducing agent and a proton acceptor to form the compound comprising Formula (I) according to the following reaction scheme:

wherein,

R 1 , R 2 , and R 3 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, hydroxyl, SH, SR 1811 , OR 1811 , and NR 1811 R 1812 ;

R 5 , R 7a , R 7b , R 8a , R 8b , R 9 , R 10a , R 10b , R 14 , R 15a , R 16a , and R 16b are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, hydroxyl, SH, SR 1811 , OR 1811 , and NR 1811 R 1812 , wherein any pair of R #a and R #b where # is chosen from 7, 8, 10, 15, and 16 may be optionally linked by groups chosen from ═O, ═S, and ═NR 1813 ;

R 17 is chosen from hydrocarbyl or substituted hydrocarbyl;

R 1811 , R 1812 , and R 1813 are independently chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

the dashed lines between the C-7 and C-8 carbons represent a carbon-carbon double bond or a carbon-carbon single bond, provided that if there is a double bond between the C-7 and C-8 carbons then only one of R 7a and R 7b is present and only one of R 8a or R 8b is present; and

provided that one or more of R 1 , R 2 , R 3 , R 5 , R 7a , R 7b , R 8a , R 8b , R 9 , R 10a , R 10b , R 14 , R 15a , R 15b , R 16a , and R 16b may be linked to form carbocyclic or heterocyclic rings;

wherein the reducing agent is selected from the group consisting of a sulfinic acid reducing agent, a hydrosulphite, a borohydride reagent, an aluminum hydride reagent, and a catalytic hydrogen transfer reduction reagent;

wherein the catalytic hydrogen transfer reduction reagent comprises a transition metal and a hydrogen donor, the transition metal being selected from the group consisting of palladium and platinum; and

wherein the process further comprises addition of a protic solvent after step (a).

6. The process of claim 5 , wherein the alkylating reagent comprises R 17 and a leaving group.

7. The process of claim 5 , wherein the alkylating reagent comprises allyl bromide.

8. The process of claim 5 , wherein R 17 is chosen from methyl, allyl, methanecyclopropyl, and methanecyclobutyl.

9. The process of claim 5 , wherein R 1 , R 2 , R 5 , R 7a , R 7b , R 8a , R 8b , R 9 , R 10a , R 10b , R 15a , R 15b , R 16a , and R 16b are hydrogen.

10. The process of claim 5 , wherein R 3 and R 14 are chosen from hydrogen, hydroxyl and OR 1811 .

11. The process of claim 5 , wherein the reducing agent is chosen from a hydrosulphite, a sulfinic acid reducing agent, a borohydride reagent, and a catalytic hydrogen transfer reduction regent.

12. The process of claim 11 , wherein the sulfinic acid reducing agent is chosen from formamidine sulfinic acid and hydroxymethane sulfinic acid.

13. The process of claim 11 , wherein the reducing agent comprises sodium hydrosulphite.

14. The process of claim 5 , wherein the C-5, C-6, C-9, C-13, and C-14 stereocenters of the compound comprising Formula (I) are chosen from RRRRR, RSRRR, RRRRS, RSRRS, RRRSR, RSRSR, RRSRR, RSSRR, SRRRR, SSRRR, RRRSS, RSRSS, RRSSR, RSSSR, SRSRR, SSSRR, SRRRS, SSRRS, SRRSR, SSRSR, RRSRS, RSSRS, RRSSS, RSSSS, SRRSS, SSRSS, SRSRS, SSSRS, SRSSR, SSSSR, SRSSS, and SSSSS, respectively, provided that the C-15 and the C-16 carbons are both either on the alpha face of the molecule or the beta face of the molecule.

15. The process of claim 5 , wherein a 6-β-epimer of the compound comprising Formula (I) is produced in a ratio of greater than 75:25 to a 6-α-epimer.

16. The process of claim 5 , wherein a 6-β-epimer of the compound comprising Formula (I) is produced in a ratio of greater than 95:5 to a 6-α-epimer.

17. The process of claim 5 , wherein a 6-α-epimer of the compound comprising Formula (I) is produced in a ratio of greater than 75:25 to a 6-β-epimer.

18. The process of claim 5 , wherein a 6-α-epimer of the compound comprising Formula (I) is produced in a ratio of greater than 95:5 to a 6-β-epimer.

19. The process of claim 5 , wherein the compound comprising Formula (II) is contacted with the alkylating reagent in an organic solvent chosen from dimethylformamide, N-methylpyrrolidinone, dimethylacetamide, and mixtures thereof.

20. The process of claim 5 , wherein the yield of the compound comprising Formula (I) is above 75%.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2013
From: WANG, PETER X.; JIANG, TAO; BERBERICH, DAVID W.
To: MALLINCKRODT LLC
Reel/Frame 029778/0584 →